Investment in securities market are subject to market risks. Read all the related documents carefully before investing
Small Cap Companies
Dominating Their Domains
See Full Details**Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
NURECA Share Price (NRCA)
Here is the latest stock price and chart of NURECA. For more details, see the NURECA company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Oct 16, 2026 11:34:00 AM | ||
|---|---|---|---|
| Price (Rs)320.00 | Open (Rs) 325.00 | High (Rs) 325.00 | Low (Rs) 320.00 |
| % Change-1.20 | Volume 561 | Value (Rs) 179,520 | 52-Week H/L 375.00 / 200.10 |
| Live NSE Quotes | Oct 16, 2026 11:17:20 AM | ||
|---|---|---|---|
| Price (Rs)324.80 | Open (Rs) 320.05 | High (Rs) 326.90 | Low (Rs) 320.05 |
| % Change1.60 | Volume 790 | Value (Rs) 256,308 | 52-Week H/L 0.00 / 0.00 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -1.20% | 1 Month -4.33% | 3 Months 17.56% | 1 Year 32.89% | 5 Years (CAGR)* -29.97% | |
* Compound Annual Growth Rate
| Valuation | ||||
|---|---|---|---|---|
| EPS (Rs)* 4.54 | P/E Ratio (x) 70.42 | Market Cap (Rs m) 3,053.41 | P/BV (x) 1.68 | Dividend Yield (%) 0.00 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
NURECA Share Price Today:
NURECA last traded price was down 1.2% to Rs 320.0 on the BSE. On the NSE, NURECA last traded price was up 1.6% to Rs 324.8. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.0%. And the benchmark S&P BSE SENSEX was at 74,659.0 (up 0.5%).
Over the last 30 days, the NURECA share price is down 0.9%. And over the last one year, NURECA share price is up 36.8%.
The current market capitalisation of NURECA stands at Rs 3,053.41 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of June 2026, company promoters held 68.09% stake in NURECA, with no shares having been pledged. To know more, check out the latest shareholding pattern of NURECA.
Before you go, here's an alert on NURECA you may want to take note of...
Upcoming Corporate Actions for NURECA
| Date | Announcement | Ex-Date |
|---|---|---|
| 21-Oct-2026 | Quarterly Results | - |
List of All Upcoming Corporate Actions
FAQs on NURECA
What is the NURECA share price today?
The last traded price of NURECA was Rs 320.0 on the BSE, down 1.2% over the previous close. On the NSE, NURECA last traded price was up 1.6% at Rs 324.8.
What is the market cap of NURECA?
The current market capitalisation of NURECA stands at Rs 3,053 m. For more information, check out the list of top 100 companies in India in terms of market cap.
What is the Earnings per share (EPS) of NURECA?
NURECA had an EPS of Rs 4.5 in the latest financial year. In the most recent quarter, the company declared an EPS of Rs 3.2.
What is the PE Ratio and PB Ratio of NURECA?
What is the Dividend Yield of NURECA?
For the financial year 2026, NURECA declared dividend amounting to Rs 0.0 per share. At the current price of Rs 320.0, this results in a dividend yield of 0.0%.
Which are the top pharmaceuticals companies in India by marketcap?
Based on marketcap, these are the top pharmaceuticals companies in India:
You can see the full list of pharmaceuticals stocks ranked by marketcap here.
Also, here's one of our more popular screens related to marketcap: India's Biggest Companies by Marketcap.
Which are the biggest pharmaceuticals companies in India by sales?
Based on sales, these are the top pharmaceuticals companies in India:
- #1 SUN PHARMA
- #2 DR. REDDYS LAB
- #3 AUROBINDO PHARMA
- #4 CIPLA
- #5 LUPIN
You can see the full list of pharmaceuticals stocks.
Curious to know which Indian companies are growing their sales at a faster rate than their peers? Check out India's Fastest Growing Companies by Sales.
Which are the biggest pharmaceuticals companies in India by net profit?
Based on net profit, these are the top pharmaceuticals companies in India:
- #1 SUN PHARMA
- #2 LUPIN
- #3 ZYDUS LIFESCIENCES
- #4 DR. REDDYS LAB
- #5 CIPLA
You can see the full list of pharmaceuticals stocks.
In case you are wondering which company logs in the biggest net profit margin in India, check this out: High Profit Margin Companies in India.
Today's Market
![]()
Sensex Today Trades Higher | Nifty Above 23,000 | IT Stocks Shine(10:30 am)
Sensex Today Trades Higher | Nifty Above 23,000 | IT Stocks ShineAsian markets traded higher on Friday, tracking gains on Wall Street as investors looked beyond the recent technology sell-off.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
- Hidden Treasure
- Forever Stocks
- Big Wave Profits
- Equitymaster Venture
- Microcap Millionaires
- Momentum Profits
- Double Income
- Midcap Value Alert
- Exponential Profits
- Annual Breakout Alert
- Lazy Millionaire
- Phase One Alert
- InsiderPro Stocks
- StockSelect
- Private Briefing
- Active Wealth Multiplier 2030
- FundSelect
- Fund Advantage
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
- Best Defence Stocks in India
- Upcoming Dividend Stocks
- Best Semiconductor Stocks in India
- Data Center Stocks in India
- Best Railway Stocks in India
- Best Solar Stocks in India
- Fastest Growing Stocks in India
- List of BSE Sensex 30 Stocks
- Adani Group Shares
- Stocks Recently Bought by FIIs in India
- Top Value Stocks in India
LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, enlistment with BSE as IA and RA, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing any content from this website whether wholly or in part, for any purpose without the permission of Quantum Information Services Private Limited is strictly prohibited and shall be deemed to be copyright infringement.
Quantum Information Services Private Limited (QIS) is a SEBI registered Research Analyst (bearing registration no INH000021128) and Investment Adviser(Reg. No: INA000000680). Consequent upon the merger of Equitymaster Research Private Limited into QIS, effective October 30, 2025 QIS owns and operates brand 'Equitymaster' and website www.equitymaster.com. This does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities and QIS including its employees, personnel, directors, associates will not be liable for any losses (direct or indirect) incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. All content and information is provided on an 'As Is' basis by QIS. Information herein is believed to be reliable but QIS does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. The services rendered by QIS are on a best effort basis. QIS does not assure or guarantee the user any minimum or fixed returns. The securities quoted, if any are for illustration only and are not recommendatory. Use of this information is at the user's own risk. The user must make his own investment decisions based on his specific investment objective and financial position and using such independent advisors as he believes necessary. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject QIS or its affiliates to any registration or licensing requirement.
The performance data quoted represents past performance and does not guarantee future results. As a condition to accessing QIS's content and website, you agree to our Terms and Conditions of Use, available here.